Anti-Human IL6 Recombinant Antibody (Siltuximab) (CAT#: TAB-212)

Recombinant monoclonal antibody to IL-6. Siltuximab (INN) (also known as CNTO 328, Anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse proteins) monoclonal antibody. It binds to interleukin-6. Siltuximab has been investigated for the treatment of metastatic renal cell cancer, prostate cancer, and Castleman's disease, among other types of cancer.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Datasheet
  • MSDS
  • COA

Figure 1 In vitro effects of siltuximab on ovarian cancer cells 2A.

In vitro inhibition of IL-6 release in IGROV-1 and TOV21G ovarian cancer cells by siltuximab (10-100μg/ml) for three days 2B. Protein was extracted from IGROV1 and TOV21G cells treated with siltuximab (Sil) or IgG control and blotted for expression of Tyr705 phospho-STAT3. 2C. In vitro inhibition of IL-6 release in both IGROV-1 and TOV21G cell lines also led to reduced release of other inflammatory cytokines and chemokines. Typical results of two experiments performed in IGROV1 cells are presented. 2D. Expression of Jagged-1 in unstimulated ovarian cancer cells was assessed by quantitative RT-PCR and immunoblot (left). Following stimulation with either 20 ng/ml IL-6, IgG control or siltuximab for 48 hours, Jagged-1 expression was assessed by quantitative RT-PCR (right). Data are representative of three independent experiments performed. *p<0.05.

Coward, J. , Kulbe, H. , Chakravarty, P. , Leader, D. , Vassileva, V. , & Leinster, D. A. , et al. (2011). Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical Cancer Research, 17(18), 6083-6096.

Figure 2 Actions of siltuximab on intraperitoneal tumors formed from IGROV-1 cells.

Luciferase bioluminescence imaging was used to measure intraperitoneal tumor burden.Siltuximab (20mg/kg twice weekly) treatment for four weeks started 1 day (left) or 14 days(right) after tumor cell injection, and significantly reduced tumor burden compared to IgGcontrol (* p < 0.05). All mice were killed after four weeks of treatment.

Coward, J. , Kulbe, H. , Chakravarty, P. , Leader, D. , Vassileva, V. , & Leinster, D. A. , et al. (2011). Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical Cancer Research, 17(18), 6083-6096.

Figure 3 Actions of siltuximab on intraperitoneal tumors formed from IGROV-1 cells.

Effects of siltuximab on IL-6, phospho-STAT3 and Jagged1 expression in the IGROV-1xenograft model following 4 weeks of siltuximab. The number of tumor cell nuclei showingpositive staining for pSTAT3 were counted in 3 randomly selected areas per tumor section(n=3) using a x40 objective with approximately 500 nuclei counted per tumor (***; p <0.0001). After 4 weeks of siltuximab treatment, there were also marked decreases in bothhuman IL-6 and Jagged1 mRNA expression. RNA from 3 tumor samples in each group wasused for this analysis. In addition, there was a reduction in Jagged-1 expression as detectedby immunohistochemistry. Main photomicrographs taken with x10 magnification lens, insetx40.

Coward, J. , Kulbe, H. , Chakravarty, P. , Leader, D. , Vassileva, V. , & Leinster, D. A. , et al. (2011). Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical Cancer Research, 17(18), 6083-6096.

Figure 4 Phase II trial of the anti-IL-6 antibody siltuximab – survival, clinical responses andpharmacokinetics.

4A. 18 women with recurrent, platinum-resistant ovarian cancer received bi-weeklyinfusions of siltuximab. Patients were re-staged after 3 (12 patients) or 5 (6 patients) dosesand every 12 weeks thereafter. Those achieving Stable Disease (SD) after 3 – 5 dosescontinued treatment for up to 17 infusions. The median progression-free and overallsurvival, PFS and OS respectively, of the patients who received at least one infusion ofsiltuximab was 12 and 49 weeks respectively.4B. CA125 was measured at enrolment and prior to each infusion of siltuximab. Patient 13had a CA125 response by GCIG criteria. PET/CT images at baseline, Week 9 (5 cycles),Week 23 (12 cycles) indicated reduction in [18F]-FDG uptake in pelvic tumors. The regionof high [18F]-FDG uptake anteriorly on the week 23 scan represents the bladder. ULN:Upper Limit of Normal4C. CA125 values prior to and during siltuximab treatment. Patients 5, 9 and 10 hadreductions in CA125 lasting up to 12 weeks. In patient 20, there was a highly significantchange in CA125 doubling time slope after commencing treatment.4D. Siltuximab pharmacokinetics. Serum siltuximab levels were measured immediatelyprior to (Cmin) and one hour after (Cmax) the first three doses of siltuximab.

Coward, J. , Kulbe, H. , Chakravarty, P. , Leader, D. , Vassileva, V. , & Leinster, D. A. , et al. (2011). Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical Cancer Research, 17(18), 6083-6096.

Figure 5 IL-6–dependent upregulation of pStat3 expression and effect of siltuximab.

A, Hamster kidney BHKpEGFP-Stat3 and ovarian cancer cell line SKOV-3 cells were treated with 30 ng/mL IL-6 for 1 hour as indicated. B, Cell lysates were subjected to Western blot analysis with anti- pStat3, or anti-b-actin antibodies as described in Materials and Methods.

Guo, Y. , Nemeth, J. , O"Brien, C. , Susa, M. , Liu, X. , & Zhang, Z. , et al. (2010). Effects of siltuximab on the il-6-induced signaling pathway in ovarian cancer. Clinical Cancer Research, 16(23), 5759-5769.

Figure 6 Confirmation of (A) UGT2B4 and (B) ATP2B2 mRNA expression in IL-6/ siltuximab treated cell lines by real-time RT-PCR.

Real-time RT-PCR was performed as described in Materials and Method. The relative levels of gene expression were calculated from the relevant signals by normalization with the signal for actin expression.

Guo, Y. , Nemeth, J. , O"Brien, C. , Susa, M. , Liu, X. , & Zhang, Z. , et al. (2010). Effects of siltuximab on the il-6-induced signaling pathway in ovarian cancer. Clinical Cancer Research, 16(23), 5759-5769.

Figure 7 Effect of siltuximab on paclitaxel sensitivity in ovarian cancer drug resistant cells.

SKOV-3TR and Caov-3TR cells at 2 Â 103 cells per well were plated in 96-well plates in culture medium containing different concentrations of siltuximab and paclitaxel. After 96 hours of culture, effect of siltuximab on paclitaxel-induced cell death were determined by MTT assay as described in Materials and Methods. A, Effect of siltuximab on paclitaxel sensitivity in SKOV-3TR. C, Effect of siltuximab on paclitaxel sensitivity in Caov-3TR. Statistical analysis was performed by a 2-sided Student's t-test in SKOV-3TR (B) and Caov-3TR (D). Cell viability was assessed using the MTT and recorded as percent viability relative to the untreated control cells. Error bars are SD of averaged results and P < 0.05 were accepted as a significant difference between means. Values are representative of triplicate determinations in 2 or more experiments.

Guo, Y. , Nemeth, J. , O"Brien, C. , Susa, M. , Liu, X. , & Zhang, Z. , et al. (2010). Effects of siltuximab on the il-6-induced signaling pathway in ovarian cancer. Clinical Cancer Research, 16(23), 5759-5769.

Figure 8 Siltuximab inhibits IL-6–induced EGFP-Stat3 nuclear translocation.

SKOV-3 pEGFP-Stat3 and BHKpEGFP-Stat3 cells which stably express the EGFP-Stat3 fusion protein were incubated for 4 hours with siltuximab (0, 0.001, 0.1, 1.0, 10.0 μg/mL) followed immediately thereafter with the addition of IL-6 to a final concentration of 30 ng/mL. Subcellular localization of the fusion protein was assessed by fluorescence microscopy. A, Effects of siltuximab on IL-6–induced stat3 nuclear translocation in BHKpEGFP-Stat3 cells. B, Effects of siltuximab on IL-6–induced stat3 nuclear translocation in SKOV-3pEGFP-Stat3 cells. Arrow labels () show the IL-6–induced Sta3 nucleocytoplasmic shuttling and arrow labels () show the effect of siltuximab (at different doses) on the IL-6–induced Stat3 nuclear translocation.

Guo, Y. , Nemeth, J. , O"Brien, C. , Susa, M. , Liu, X. , & Zhang, Z. , et al. (2010). Effects of siltuximab on the il-6-induced signaling pathway in ovarian cancer. Clinical Cancer Research, 16(23), 5759-5769.


Specifications

  • Immunogen
  • recombinant human IL-6.
  • Host Species
  • Mouse
  • Derivation
  • Chimeric (mouse/human)
  • Type
  • IgG1 - kappa
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • IF, IP, Neut, FuncS, ELISA, FC, ICC
  • Trade name
  • Sylvant
  • CAS
  • 541502-14-1
  • Generic Name
  • Siltuximab
  • ATC Code
  • L04AC11
  • UNII
  • T4H8FMA7IM
  • MW
  • 145.0 kDa
  • Related Disease
  • Neoplasms

Applications

  • Application Notes
  • The IL6 antibody has been reported in applications of Inhib, Luciferase, IHC, PK, WB, RT-PCR, MTT, IF.

Target

  • Alternative Names
  • Siltuximab;Sylvant;541502-14-1;CNTO-328;cCLB8;Sylvant;CNTO 328;anti-IL-6 chimeric monoclonal antibody;cCLB8;IL6;interleukin 6 (interferon, beta 2);IFNB2;interleukin-6;BSF2;HGF;HSF;IL 6;CDF;BSF-2;IFN-beta-2;interferon beta-2;interleukin BSF-2;hybridoma gro

Related Resources

  • Biosimilar Overview
  • Related Diseases
  • Related Signaling Pathways
Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Siltuximab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Siltuximab"

Afuco™ Anti-IL6 ADCC Recombinant Antibody (Siltuximab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL-6. Siltuximab (INN) (also known as CNTO 328, Anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse proteins) monoclonal antibody. It binds to interleukin-6. Siltuximab has been investigated for the treatment of metastatic renal cell cancer, prostate cancer, and Castleman's disease, among other types of cancer.

See other products for "IL6"

Mouse Antibody

CAT Product Name Application Type
TAB-239 Anti-Human IL6 Recombinant Antibody (Elsilimomab) WB, FuncS, IF, Neut, ELISA, FC, IP IgG1
TAB-0171CL Mouse Anti-IL6 Recombinant Antibody (TAB-0171CL) ELISA, Block, In vivo Mouse IgG
TAB-0022CL-F(E) Mouse Anti-IL6 Recombinant Antibody; Fab Fragment (TAB-0022CL-F(E)) Elisa, In vivo, FuncS, Block Mouse Fab
TAB-0023CL-F(E) Mouse Anti-IL6 Recombinant Antibody; Fab Fragment (TAB-0023CL-F(E)) Elisa, In vivo, FuncS, Block Mouse Fab
TAB-0024CL-F(E) Mouse Anti-IL6 Recombinant Antibody; Fab Fragment (TAB-0024CL-F(E)) Elisa, In vivo, FuncS, Block Mouse Fab

Human Antibody

CAT Product Name Application Type
TAB-097 Anti-Human IL6 Recombinant Antibody (Sirukumab) FC, IP, ELISA, Neut, FuncS, IF, WB IgG1 - kappa
TAB-680LC Human Anti-IL6 Recombinant Antibody (TAB-680LC) ELISA, FuncS Human IgG1
TAB-681LC Human Anti-IL6 Recombinant Antibody (TAB-681LC) ELISA, FuncS Human IgG1
TAB-682LC Human Anti-IL6 Recombinant Antibody (TAB-682LC) ELISA, FuncS Human IgG1
TAB-683LC Anti-human IL6 Recombinant Antibody (IL6gk3-2) (TAB-683LC) ELISA, SPR, FuncS Human antibody

Fab Fragment Antibody

CAT Product Name Application Type
PFBL-613 Recombinant Human Anti-IL-6 Antibody Fab Fragment ELISA, Neut Fab
HPAB-0164-YJ-F(E) Mouse Anti-IL6 Recombinant Antibody (clone 6yl-9); Fab Fragment ELISA, WB, Inhib, Neut Mouse Fab
HPAB-0876-FY-S(P) Human Anti-IL6 Recombinant Antibody; scFv Fragment (HPAB-0876-FY-S(P)) ELISA Human scFv
HPAB-0877-FY-S(P) Human Anti-IL6 Recombinant Antibody; scFv Fragment (HPAB-0877-FY-S(P)) ELISA Human scFv
HPAB-0089-WJ-F(E) Human Anti-IL6 Recombinant Antibody; Fab Fragment (HPAB-0089-WJ-F(E)) ELISA, WB Humanized Fab

Chimeric Antibody

CAT Product Name Application Type
TAB-0026CL Human Anti-IL6 Recombinant Antibody (TAB-0026CL) Elisa, In vivo, FuncS, Block Chimeric (mouse/human) IgG
TAB-0026CL-S(P) Mouse Anti-IL6 Recombinant Antibody; scFv Fragment (TAB-0026CL-S(P)) Elisa, In vivo, FuncS, Block Mouse scFv
TAB-670LC Anti-human IL6 Recombinant Antibody (NTS) (TAB-670LC) ELISA, Inhib Chimeric antibody (mouse/human)
TAB-670LC-S(P) Anti-human IL6 scFv Fragment (NTS) ELISA Chimeric antibody (mouse/human)
TAB-670LC-F(E) Anti-human IL6 Fab Fragment (NTS) ELISA Chimeric antibody (mouse/human)

Humanized Antibody

CAT Product Name Application Type
TAB-0172CL Human Anti-IL6 Recombinant Antibody (TAB-0172CL) ELISA, Block, In vivo Human IgG
TAB-0173CL Human Anti-IL6 Recombinant Antibody (TAB-0173CL) ELISA, Block, In vivo Human IgG1
TAB-0172CL-S(P) Human Anti-IL6 Recombinant Antibody; scFv Fragment (TAB-0172CL-S(P)) ELISA, Block, In vivo Human scFv
TAB-0173CL-S(P) Human Anti-IL6 Recombinant Antibody; scFv Fragment (TAB-0173CL-S(P)) ELISA, Block, In vivo Human scFv
TAB-678LC-S(P) Anti-human IL6 scFv Fragment (BA399) ELISA, FC Humanized antibody

Fab Glycosylation

CAT Product Name Application Type
Gly-037LC Recombinant Anti-Human IL6 Antibody (Fab glycosylation) ELISA Humanized antibody

Deglycosylated Antibody (Non-glycosylated IgGs)

CAT Product Name Application Type
Gly-197LC Recombinant Anti-Human IL6 Antibody (Non-glycosylated) ELISA Humanized antibody

Recombinant Antibody

CAT Product Name Application Type
MOB-0632CT Recombinant Mouse anti-Human IL6 Monoclonal antibody (6708) ELISA, WB
HPAB-588-FY Human Anti-IL6 Recombinant Antibody (HPAB-588-FY) FC, ELISA Human IgG2
HPAB-591-FY Human Anti-IL6 Recombinant Antibody (HPAB-591-FY) Inhib Human IgG1
HPAB-0164-YJ Mouse Anti-IL6 Recombinant Antibody (clone 6yl-9) ELISA, WB, Inhib, Neut Mouse IgG1, κ
HPAB-0876-FY Human Anti-IL6 Recombinant Antibody (HPAB-0876-FY) ELISA Human IgG

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0284MZ Chicken Anti-Interleukin-6 Polyclonal IgY WB, Indirect ELISA Chicken antibody

Neutralizing Antibody

CAT Product Name Application Type
NEUT-1450CQ Mouse Anti-IL6 Recombinant Antibody (clone CBL596) Neut Mouse IgG2a
NEUT-1451CQ Mouse Anti-IL6 Recombinant Antibody (clone CBL661) Neut Mouse IgG2b
NEUT-1452CQ Mouse Anti-IL6 Recombinant Antibody (clone CBL553) WB, Neut Mouse IgG2a
NEUT-1453CQ Mouse Anti-IL6 Recombinant Antibody (clone CBL615) WB, Neut Mouse IgG2b
NEUT-1454CQ Mouse Anti-IL6 Recombinant Antibody (clone 1X45) IHC, Neut Mouse IgG2

Blocking Antibody

CAT Product Name Application Type
NEUT-1474CQ Rat Anti-Il6 Recombinant Antibody (clone 32C11) Block, ELISA, WB Rat IgG2a

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-1814 Rabbit Anti-IL6 Recombinant Antibody (clone DS1814AB) WB Rabbit IgG
MOR-4277 Rabbit Anti-IL6 Recombinant Antibody (clone SI360DS) ELISA Rabbit IgG
MOR-4622 Rabbit Anti-IL6 Recombinant Antibody (clone TH135DS) WB, ELISA Rabbit IgG
MOR-4623 Rabbit Anti-IL6 Recombinant Antibody (clone TH136DS) WB Rabbit IgG

MHC Tetramer for Cancer

CAT Product Name Application Type
MHC-LC3429 PE-B8/Human IL6 (ILKQKIALD) MHC Tetramer FCM
MHC-LC3430 PE-B8/Human IL6 (ILKQKIALD) MHC Tetramer FCM

scFv Fragment Antibody

CAT Product Name Application Type
HPAB-0017-YC-S(P) Human Anti-IL6 Recombinant Antibody; scFv Fragment (HPAB-0017-YC-S(P)) ELISA, Block Human scFv
HPAB-0824-CN-S(P) Human Anti-IL6 Recombinant Antibody (clone Ab18); scFv Fragment ELISA Human scFv
HPAB-0825-CN-S(P) Human Anti-IL6 Recombinant Antibody (clone 18E); scFv Fragment ELISA Human scFv
HPAB-S0082-YC-S(P) Rabbit Anti-IL6 Recombinant Antibody; scFv Fragment (HPAB-S0082-YC-S(P)) ELISA, Block Rabbit scFv
HPAB-S0083-YC-S(P) Rabbit Anti-IL6 Recombinant Antibody; scFv Fragment (HPAB-S0083-YC-S(P)) ELISA, Block Rabbit scFv

Neuroscience Antibody

CAT Product Name Application Type
NS-043CN Human Anti-IL6 Recombinant Antibody (NS-043CN) ELISA, WB Human IgG1
NS-043CN-F(E) Human Anti-IL6 Recombinant Antibody; Fab Fragment (NS-043CN-F(E)) ELISA, WB Human Fab
NS-043CN-S(P) Human Anti-IL6 Recombinant Antibody; scFv Fragment (NS-043CN-S(P)) ELISA, WB Human scFv

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-239 Afuco™ Anti-IL6 ADCC Recombinant Antibody (Elsilimomab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC ADCC enhanced antibody
AFC-TAB-097 Afuco™ Anti-IL6 ADCC Recombinant Antibody (Sirukumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody
AFC-TAB-212 Afuco™ Anti-IL6 ADCC Recombinant Antibody (Siltuximab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-H26 Afuco™ Anti-IL6 ADCC Recombinant Antibody (Enlimomab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody
AFC-TAB-253 Afuco™ Anti-IL6 ADCC Recombinant Antibody (Olokizumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF ADCC enhanced antibody

Single-domain Antibody

CAT Product Name Application Type
HPAB-S0171-YC Camelid Anti-IL6 Recombinant Single Domain Antibody (clone 7G9) ELISA, Inhib Camelid VHH
HPAB-S0172-YC Camelid Anti-IL6 Recombinant Single Domain Antibody (clone 13F12) ELISA, Inhib Camelid VHH
HPAB-S0173-YC Camelid Anti-IL6 Recombinant Single Domain Antibody (clone 21E7) ELISA, Inhib Camelid VHH
HPAB-S0174-YC Camelid Anti-IL6 Recombinant Single Domain Antibody (clone 17C4) ELISA, Inhib Camelid VHH
HPAB-S0175-YC Camelid Anti-IL6 Recombinant Single Domain Antibody (clone 13A1) ELISA, Inhib Camelid VHH

Customer Reviews and Q&As

Submit a review or a question
Thare are currently no Customer reviews or questions for TAB-212. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

* Abbreviations
3D IHC3D Immunohistochemistry
ActivActivation
AgonistAgonist
ApopApoptosis
BABioassay
BIBioimaging
BlockBlocking
Cell ScreeningCell Screening
SeparationCell Separation
ChIPChromatin Immunoprecipitation
CMCDComplement Mediated Cell Depletion
CostimCostimulation
CytCytotoxicity
DepletionDepletion
DBDot Blot
EMElectron Microscopy
ELISAEnzyme-linked Immunosorbent Assay
ELISPOTEnzyme-linked Immunosorbent Spot
FCFlow Cytometry
FuncSFunctional Assay
GSGel Super Shift Assay
HAHemagglutination
IAImmunoassay
IBImmunoblotting
ICCImmunocytochemistry
IDImmunodiffusion
IFImmunofluorescence
IHCImmunohistochemistry
IHC-FrImmunohistochemistry-Frozen
IHC-PImmunohistochemistry-Paraffin
REImmunohistology - Resin Sections
IPImmunoprecipitation
IRMAImmunoradiometric Assay
SHIn situ hybridization
InhibInhibition
ICFCIntracellular Staining for Flow Cytometry
KO/KD-WBKnockout/Knockdown target confirmation by Western Blot
Live cell imagingLive cell imaging
CyTOF®Mass Cytometry
MeDIPMethylated DNA Immunoprecipitation
MultiplexMultiplex bead-based assay
NeutNeutralization
PPProtein Purification
PGProteogenomics
RIRadial Immunodiffusion
RIARadioimmunoassay
StimStimulation
SPRSurface Plasmon Resonance
TCTissue Culture
TBTurbidimetry
WBWestern Blot

Send Inquiry

© 2022 Creative BioLabs. All Rights Reserved
  • 0
  • 0

Cart